Navidea Biopharmaceuticals, Inc. NAVB, a biopharmaceutical company
focused on the development and commercialization of precision diagnostic
radiopharmaceuticals, today announced the U.S. launch of Lymphoseek^®
(technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping
procedures that are performed to help in the diagnostic evaluation of
potential cancer spread for patients with breast cancer and melanoma.
Lymphoseek was approved by the U.S. Food and Drug Administration (FDA) in
March 2013.
As part of Navidea's U.S. distribution partnership, Cardinal Health is
responsible for the sale and distribution of Lymphoseek to health care
professionals through its existing network of nuclear pharmacies. Navidea is
working closely with the company in all commercial activities and medical
education programs for Lymphoseek.
Lymphoseek has been priced at $300 per patient procedure. Navidea has been
working to ensure fair and equitable reimbursement for lymphatic mapping
procedures using Lymphoseek. In the case of Medicare, Navidea believes these
procedures are currently reimbursable under established codes, and expects to
apply for and receive a unique pass-through code for Lymphoseek within a few
months. Navidea and Cardinal Health will provide information and support to
providers and payers to ensure that they can secure formulary status and
appropriate payment.
According to the American Cancer Society, approximately 232,000 new cases of
breast cancer and 77,000 new cases of melanoma are expected to be diagnosed in
the United States in 2013. One of the procedures used by physicians to help in
the diagnostic evaluation of breast cancer and melanoma is lymphatic mapping.
Lymphatic mapping is a widely used procedure in which lymph nodes that may
contain tumor metastases are identified and biopsied to determine if cancer
has spread beyond the primary tumor. Navidea estimates that lymphatic mapping
is utilized in approximately 70% of these patients each year in the United
States.
Conference Call for Investors
Navidea Biopharmaceuticals will host a conference call for investors, today at
8:30 a.m. EDT to discuss the Lymphoseek launch. Conference call dial-in
information is included below.
Conference Call Information
TO PARTICIPATE LIVE: TO LISTEN TO A REPLAY:
Date: May 1, Available until: May 15,
2013 2013
Time: 8:30 a.m. Toll-free (U.S.) (877)
EDT Dial in # : 660-6853
International (201)
Dial in # : 612-7415
Toll-free (U.S.) (877)
Dial in # : 407-8031
International (201)
Dial in # : 689-8031
Replay passcode: 268
Account #: 413373
Conference ID #:
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in